DisclosureWe earn commission on partner links; ranking is set by clinician-vetted methodology — not advertisers.
When do patents expire on Wegovy, Ozempic, Mounjaro, Zepbound, Saxenda? Country-by-country tracker. Liraglutide generic launched Dec 2024 — semaglutide India/Canada/China 2026, US 2031.
Victoza, Saxenda · Novo Nordisk · Approved 2010
First GLP-1 to go generic. Hikma's generic liraglutide approved by FDA December 23, 2024 — first GLP-1 generic in US market. Canada and EU followed Q1 2025.
| Country | Status | Expiration |
|---|---|---|
| United States | Expired | Dec 2024 |
| Canada | Expired | Feb 2025 |
| European Union | Expired | Sep 2024 |
| United Kingdom | Expired | Oct 2024 |
| India | Expired | Jun 2023 |
| China | Expired | Mar 2024 |
| Japan | Active | Jun 2027 |
| Australia | Expired | Apr 2025 |
| Brazil | Expired | Aug 2024 |
| Mexico | Expired | May 2024 |
Ozempic, Wegovy, Rybelsus, Wegovy Pill · Novo Nordisk · Approved 2017
Biggest patent cliff in pharma history pending. US patent extends to 2031 with pediatric exclusivity extension. India, China, Canada lose composition patent 2026. Generic price expected 70-85% below brand once competition arrives.
| Country | Status | Expiration |
|---|---|---|
| United States | Active | Dec 2031 |
| Canada | Expired | Jan 2026 |
| European Union | Active | Mar 2031 |
| United Kingdom | Expired | Jan 2026 |
| India | Expired | Mar 2026 |
| China | Expired | Apr 2026 |
| Japan | Active | Oct 2031 |
| Australia | Active | Nov 2031 |
| Brazil | Active | Mar 2029 |
| Mexico | Expiring soon | Sep 2026 |
Newest major GLP-1 — patent landscape extends furthest. Composition patent valid in major markets through 2036-2037. Foundayo (oral) launched April 2026 reset some method-of-use patents to 2046+. No generic threat near-term.
| Country | Status | Expiration |
|---|---|---|
| United States | Active | Jul 2036 |
| Canada | Active | Nov 2036 |
| European Union | Active | Sep 2036 |
| United Kingdom | Active | Sep 2036 |
| India | Active | Apr 2030 |
| China | Active | Aug 2030 |
| Japan | Active | Sep 2036 |
| Australia | Active | Sep 2036 |
| Brazil | Active | Jan 2035 |
| Mexico | Active | Apr 2031 |
Trulicity · Eli Lilly · Approved 2014
Once-weekly Eli Lilly diabetes GLP-1. Patent expirations approaching faster than tirzepatide. Less prescribed since superior tirzepatide launch, but generic launch will commoditize segment.
| Country | Status | Expiration |
|---|---|---|
| United States | Active | Oct 2027 |
| Canada | Active | Sep 2027 |
| European Union | Active | Dec 2027 |
| India | Expired | Apr 2025 |
| China | Expired | Jun 2025 |
| Japan | Active | Dec 2027 |
Semaglutide composition patent extends to December 2031 in the US, plus 6-month pediatric exclusivity. Generic launch unlikely before 2031. Teva and Mylan/Viatris have filed Paragraph IV challenges, but settlement is more likely than early launch.
Different patent terms in each country based on filing dates and local IP law. India and Canada's semaglutide patents expire in 2026, while US extensions push to 2031. Brazil, Mexico, China also expire earlier than US.
No. FDA prohibits personal importation of foreign generics, even from countries where they're legally manufactured. Customs routinely intercepts these shipments. Travel-personal-supply is a gray area but technically also prohibited.
Tirzepatide composition patents extend to 2036-2037 in major markets. Foundayo (oral tirzepatide) has fresh method-of-use patents to 2046. Tirzepatide will be the last-to-generic of the major GLP-1s.
Generic liraglutide (Hikma, 2024) launched at ~$300/mo, 70% below brand Saxenda. Generic semaglutide is expected to follow similar trajectory — initial generic pricing 30-40% of brand, dropping to 10-20% of brand within 18 months of multi-source competition.
Patent dates sourced from WIPO, USPTO, EMA, public manufacturer disclosures. Some patents extended by pediatric exclusivity (6 months), Patent Term Extensions, or SPCs. We update quarterly as challenges and settlements emerge.